Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | P449T |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | PIK3CA P449T lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P449T results in increased Pik3ca kinase activity in cell culture (PMID: 20530683), and therefore, is predicted to lead to a gain of Pik3ca protein function. |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA P449T PIK3CA mutant PIK3CA exon8 PIK3CA P449T |
Transcript | NM_006218.4 |
gDNA | chr3:g.179210279C>A |
cDNA | c.1345C>A |
Protein | p.P449T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011512894 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179210279C>A | c.1345C>A | p.P449T | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA P449T | colorectal cancer | sensitive | Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, Miransertib (ARQ092) treatment induced cell death and inhibited proliferation of a colorectal cancer cell line harboring PIK3CA P449T in culture (PMID: 32439931). | 32439931 |
PIK3CA P449T | colorectal cancer | predicted - sensitive | Ipatasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Ipatasertib (GDC-0068) treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA P449T in culture (PMID: 32439931). | 32439931 |
PIK3CA P449T | colorectal cancer | sensitive | MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, MK2206 treatment induced cell death and inhibited proliferation of a colorectal cancer cell line harboring PIK3CA P449T in culture (PMID: 32439931). | 32439931 |
PIK3CA P449T | colorectal cancer | sensitive | GSK690693 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK690693 treatment induced cell death and inhibited proliferation of a colorectal cancer cell line harboring PIK3CA P449T in culture (PMID: 32439931). | 32439931 |
PIK3CA P449T | colorectal cancer | sensitive | ARQ 751 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 751 treatment induced cell death and inhibited proliferation of a colorectal cancer cell line harboring PIK3CA P449T in culture (PMID: 32439931). | 32439931 |